Skip to main content

Posts

Showing posts with the label australia

#Surveillance and follow up #outcomes of #myocarditis after #mRNA #COVID19 #vaccination in #Australia

Abstract Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern . We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia . Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild , with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-ri...

#Management and #outcomes of #children hospitalised with #COVID19 including Incidental and Nosocomial infections in #Australia 2020-2023: a national surveillance study

Highlights •  Acute COVID-19 usually causes mild illness even in young and immunosuppressed children •  Nosocomial SARS-CoV-2 infection is associated with more severe disease •  Concurrent serious bacterial infection is rare in children admitted with acute COVID-19. ABSTRACT Background Management and outcomes of children hospitalised with acute SARS-CoV-2 infection may differ throughout the pandemic or with admission type (clinical COVID-19, incidental COVID-19 or nosocomial infection). Objectives Describe the severity, management and outcomes of hospitalised children with acute SARS-CoV-2 infection in Australia across the first 4 years of the pandemic and compare between admission types, SARS-CoV-2 variants, age groups and immune status. Study design A multi-centre prospective cohort study of 6,009 children aged 0-16 years between January 2020 to June 2023. Results Most children (84.3%) did not receive respiratory support , 33.4% received antibiotics and 8% were admitted...

#Australia - High pathogenicity avian #influenza #H7N8 viruses (#poultry) (Inf. with) - Immediate notification

This is a confirmed case of H7N8 HPAI in a free-range commercial egg layer poultry farm . H7N8 virus is genetically related to strains detected in wild birds in Australia but different from the strains detected and eradicated in Australia in 2024. Biosecurity controls ( quarantine ) have been implemented on the farm. A detailed surveillance plan is being developed and epidemiological investigation and tracing is underway. Operational activities have commenced immediately. A Control Area (CA) and Restricted Area (RA) have been declared around the premises. Movement controls are being implemented in the CA and RA. A public information strategy has been employed. All coordinates provided are approximate to the nearest town location. Outbreak location: Victoria State. Source: WOAH,  https://wahis.woah.org/#/in-review/6249 _____